Wealthfront Advisers LLC Reduces Position in Pfizer Inc. $PFE

Wealthfront Advisers LLC decreased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 18.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 672,665 shares of the biopharmaceutical company's stock after selling 151,684 shares during the period. Wealthfront Advisers LLC's holdings in Pfizer were worth $16,198,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Evolution Wealth Management Inc. grew its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new position in Pfizer during the fourth quarter worth approximately $26,000. Keb Asset Management LLC purchased a new position in Pfizer during the second quarter worth approximately $26,000. HFM Investment Advisors LLC boosted its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 427 shares during the last quarter. Finally, Global Trust Asset Management LLC grew its holdings in Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 650 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $28.00 on Friday. The stock has a market cap of $159.59 billion, a PE ratio of 36.84 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The stock has a fifty day simple moving average of $25.30 and a 200-day simple moving average of $26.25.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company's quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer's dividend payout ratio (DPR) is currently 226.32%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PFE shares. JPMorgan Chase & Co. cut their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Wednesday, July 8th. Guggenheim lowered their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Weiss Ratings lowered shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 17th. HSBC lowered shares of Pfizer from a "buy" rating to a "hold" rating and decreased their target price for the company from $32.00 to $28.00 in a report on Monday, July 6th. Finally, UBS Group restated a "neutral" rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source